Immunological requirements for rejection and tolerance induction differ between various organs. While memory CD8 + T cells are considered a barrier to immunosuppressionmediated acceptance of most tissues and organs, tolerance induction after lung transplantation is critically dependent on central memory CD8 + T lymphocytes. Here we demonstrate that costimulation blockade-mediated tolerance after lung transplantation is dependent on programmed cell death 1 (PD-1) expression on CD8 + T cells. In the absence of PD-1 expression, CD8 + T cells form prolonged interactions with graftinfiltrating CD11c + cells; their differentiation is skewed towards an effector memory phenotype and grafts are rejected acutely. These findings extend the notion that requirements for tolerance induction after lung transplantation differ from other organs.
Immunological requirements for rejection and tolerance induction differ between various organs. While memory CD8 + T cells are considered a barrier to immunosuppressionmediated acceptance of most tissues and organs, tolerance induction after lung transplantation is critically dependent on central memory CD8 + T lymphocytes. Here we demonstrate that costimulation blockade-mediated tolerance after lung transplantation is dependent on programmed cell death 1 (PD-1) expression on CD8 + T cells. In the absence of PD-1 expression, CD8 + T cells form prolonged interactions with graftinfiltrating CD11c + cells; their differentiation is skewed towards an effector memory phenotype and grafts are rejected acutely. These findings extend the notion that requirements for tolerance induction after lung transplantation differ from other organs.
Thus, immunosuppressive strategies for lung transplant recipients need to be tailored based on the unique immunological properties of this organ.
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| INTRODUCTION
Immune responses after lung transplantation differ from those observed after transplantation of other organs. 1, 2 Our previous work has established that interactions between innate and adaptive immune cell populations within lung allografts regulate both rejection and tolerance. 1, 3 This sets the lung apart from other organs and tissues such as hearts and pancreatic islets, where graft rejection and tolerance depend on cell trafficking to graft-draining secondary lymphoid organs. 4, 5 Based on this unique local environment, lung grafts have been referred to as "lymph nodes with alveoli." 6 The capacity to generate alloimmune responses locally may provide an explanation of why conditions such as primary graft dysfunction and respiratory infections, which are associated with infiltration of immune cells into lung grafts, can predispose to immune-mediated graft failure. 
| Lung transplantation
Left orthotopic vascularized lung transplants were performed as previously described. 
| Histology
Portions of transplanted lungs were fixed in formaldehyde, sectioned, and stained with hematoxylin and eosin. Grading for acute cellular rejection was performed in a blinded manner by a pathologist (JHR) using standard criteria. 
| Flow cytometry
Single cell suspensions were prepared from lung allografts, draining mediastinal lymph nodes, and spleens as previously described and incubated with CD16/32 antibody 30 minutes prior to the staining with fluorochrome-labeled antibodies specific for CD90. 
| Measurement of serum alloantibody titers
Two hundred microliter aliquots of phosphate-buffered saline with 0.5% bovine serum albumin and 0.02% sodium azide (PBA) containing 
| Statistics
Data are reported as mean ± SEM. The Mann-Whitney U test was performed using GraphPad Prism version 7.0 (GraphPad Software, La
Jolla, CA). P < .05 was considered significant.
| RESULTS

| PD-1 blockade prevents induction of lung transplant tolerance
Based on previous reports that inhibition of PD-1/PD-L1 can accelerate rejection of hearts and pancreatic islets, we set out to evaluate the role of this inhibitory pathway in tolerance after lung transplantation. 10, 11 We transplanted BALB/c lungs into B6 recipients that were treated with peri-operative costimulatory blockade. When these recipients were treated with anti-PD-1 antibody 2 days prior and 2 days after transplantation, pulmonary allografts were acutely rejected ( Figure 1A ,B). Consistent with previous findings, graft rejection was associated with a significant increase in the ratio of CD8 + T cells to CD4 + T cells within lung allografts ( Figure 1C ). 12 While we observed an increase in the percentage of proliferating cells for both CD8 + and CD4 + T lymphocytes after injection of anti-PD-1 antibody, this increase was more pronounced for CD8 + T cells ( Figure 1D ).
We also found that a higher proportion of graft-infiltrating CD4 + T cells expressed Foxp3 when PD-1 is inhibited ( Figure 1E 
| PD-1 expression on CD8 + T cells is critical for lung transplant tolerance induction
Of note, the vast majority of CD11c + antigen-presenting cells within accepted lung allografts express PD-L1 and a portion of graftinfiltrating CD8 + T cells expresses PD-1 ( Figure 2A phenotype when CD8 + T cells lacked expression of PD-1 ( Figure 3B ).
F I G U R E 2 PD-1 expression on CD8 + T cells is critical to induce tolerance after lung transplantation. (A) Representative contour plot
Furthermore, compared to central memory T cells, both wildtype and
PD-1-deficient effector memory T cells expressed higher levels of per-
forin, suggesting higher cytotoxic potential ( Figure 3C ).
| PD-1 expression regulates the interaction between CD8 + T cells and CD11c + antigen-presenting cells in lung allografts
We have previously shown that the duration of interactions between CD8 + T cells and CD11c + antigen-presenting cells within lung allografts impacts outcomes after lung transplantation. 
| DISCUSSION
Previous studies have examined the role of the PD-1 pathway in the survival of allografts. Long-term survival of allogeneic murine hearts could not be induced by anti-CD154 antibodies and donor splenocyte transfusion when the PD-1/PD-L1 pathway was inhibited.
17
Here, PD-1 expression on CD4 + T cells was found to blunt their proliferative responses, inhibit their production of proinflammatory cytokines, and promote their induction of anergy. 17 Similarly, blockade of PD-1/PD-L1 abrogated cardiac allograft tolerance induced by treatment with CTLA4-Ig. 10 Graft rejection was associated with an expansion of effector memory CD8 + T cells in the recipients' spleens and-unlike our observations in lung allografts-a decrease in the abundance of CD4 + Foxp3 + regulatory T cells in heart allografts.
Blockade of PD-1/PD-L1 triggered rejection of long-term surviving skin grafts in recipients that had been treated perioperatively with
anti-CD28 and anti-CD40L. 18 Mechanistically, residual alloreactive T cells, which express PD-1, exhibited enhanced proliferation and acquired effector function such as production of inflammatory cytokines. Spontaneous acceptance of mouse liver allografts can be abrogated by inhibiting PD-L1. 19 Rejected livers were infiltrated with CD8 + cytotoxic T lymphocytes, and expression levels of genes associated with these cells such as perforin and granzyme B were increased in the grafts. Our studies extend these previous observations and add new mechanistic insight into the role of the PD-1 pathway in lung allograft survival.
We have previously shown that central memory CD8 + T cells mediate pulmonary graft acceptance in recipients that are treated with perioperative costimulatory blockade, while effector memory CD8 + T cells trigger rejection, which may in part be due to higher expression levels of inflammatory and cytotoxic molecules. infections. 14 We speculate that the nature of the inflammatory stimuli may in part account for differences in the observations in these studies. Collectively, our findings extend the notion that-in contrast to other transplanted organs and tissues, where T cells encounter antigen-presenting cells in draining lymph nodes-interactions between immune cells within lung allografts can shape their fate. 45 Thus, local targeting of immune pathways within lungs may be a promising avenue to ameliorate rejection.
